A Study of TAS-205 for Duchenne Muscular Dystrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

TAS-205

"* Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"

DRUG

Placebo

"* Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"

Trial Locations (1)

187-8551

National Center of Neurology and Psychiatry, Tokyo

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT02246478 - A Study of TAS-205 for Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter